170 related articles for article (PubMed ID: 37808404)
1. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.
Gide TN; Paver EC; Yaseen Z; Maher N; Adegoke N; Menzies AM; Pires da Silva I; Wilmott JS; Long GV; Scolyer RA
Oncoimmunology; 2023; 12(1):2261248. PubMed ID: 37808404
[TBL] [Abstract][Full Text] [Related]
2. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
3. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients.
Gide TN; Silva IP; Quek C; Ahmed T; Menzies AM; Carlino MS; Saw RPM; Thompson JF; Batten M; Long GV; Scolyer RA; Wilmott JS
Oncoimmunology; 2020; 9(1):1659093. PubMed ID: 32002281
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
5. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
Abi-Aad SJ; Zouein J; Chartouni A; Naim N; Kourie HR
Immunotherapy; 2023 Jun; 15(8):611-618. PubMed ID: 37009648
[TBL] [Abstract][Full Text] [Related]
7. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
11. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
12. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
13. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
14. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
Smithy JW; Moore LM; Pelekanou V; Rehman J; Gaule P; Wong PF; Neumeister VM; Sznol M; Kluger HM; Rimm DL
J Immunother Cancer; 2017; 5():25. PubMed ID: 28331615
[TBL] [Abstract][Full Text] [Related]
15. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
17. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
18. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
[TBL] [Abstract][Full Text] [Related]
19. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
Adegoke NA; Gide TN; Mao Y; Quek C; Patrick E; Carlino MS; Lo SN; Menzies AM; Pires da Silva I; Vergara IA; Long G; Scolyer RA; Wilmott JS
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865395
[TBL] [Abstract][Full Text] [Related]
20. Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.
Gide TN; Allanson BM; Menzies AM; Ferguson PM; Madore J; Saw RPM; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Histopathology; 2019 May; 74(6):817-828. PubMed ID: 30589949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]